Director Of Collegium Pharmaceutical Sold $400K In Stock - Collegium Pharmaceutical ( NASDAQ:COLL )
On August 12, a recent SEC filing unveiled that John G. Freund MD, Director at Collegium Pharmaceutical COLL made an insider sell. What Happened: MD's decision to sell 11,659 shares of Collegium Pharmaceutical was revealed in a Form 4 filing with the U.S. Securities and Exchange Commission on ...
Collegium Pharmaceutical ( COLL ) Q2 Earnings and Revenues Surpass Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of +3.70% and +4.23%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook
- Generated Record Quarterly Net Revenue of $188.0 Million, Up ...
Inotiv, Inc. ( NOTV ) Reports Q3 Loss, Tops Revenue Estimates
Inotiv (NOTV) delivered earnings and revenue surprises of +20.00% and +4.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zevra Therapeutics ( ZVRA ) Reports Next Week: Wall Street Expects Earnings Growth
Zevra Therapeutics (ZVRA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium Pharmaceutical ( COLL ) Q2 Earnings Preview: What's in the Cards?
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts See a 33.91% Upside in Collegium Pharmaceutical ( COLL ) : Can the Stock Really Move This High?
The consensus price target hints at a 33.9% upside potential for Collegium Pharmaceutical (COLL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Are Investors Undervaluing Collegium Pharmaceutical ( COLL ) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
John G. Freund MD At Collegium Pharmaceutical Decides to Exercises Options Worth $243K - Collegium Pharmaceutical ( NASDAQ:COLL )
A significant insider transaction involving the exercise of company stock options was reported on June 11, by John G. Freund MD, Director at Collegium Pharmaceutical COLL, as per the latest SEC filing. What Happened: In an insider options sale disclosed in a Form 4 filing on Wednesday with the ...
Collegium Announces $25 Million Accelerated Share Repurchase Program
STOUGHTON, Mass., May 12, 2025 ( GLOBE NEWSWIRE ) -- Collegium Pharmaceutical, Inc. ( Nasdaq: COLL ) , a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share ...
Collegium Announces $25 Million Accelerated Share Repurchase Program - Collegium Pharmaceutical ( NASDAQ:COLL )
STOUGHTON, Mass., May 12, 2025 ( GLOBE NEWSWIRE ) -- Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical ( COLL ) Q1 Earnings and Revenues Surpass Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 4.20% and 3.08%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
ElectroCore, Inc. ( ECOR ) Reports Q1 Loss, Misses Revenue Estimates
electroCore (ECOR) delivered earnings and revenue surprises of 16.07% and 1.12%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical ( COLL ) Expected to Beat Earnings Estimates: Should You Buy?
Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Collegium Pharmaceutical ( COLL ) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors
FLORHAM PARK, N.J., April 16, 2025 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. ( Nasdaq: PHAT ) , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of ...
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors - Cidara Therapeutics ( NASDAQ:CDTX ) , Phathom Pharmaceuticals ( NASDAQ:PHAT )
FLORHAM PARK, N.J., April 16, 2025 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. PHAT, a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of Directors.
Collegium Announces Updates to its Board of Directors and Executive Leadership Team
- Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire from Board ...
Collegium Announces Updates to its Board of Directors and Executive Leadership Team - Collegium Pharmaceutical ( NASDAQ:COLL )
- Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire from Board - - Dr. Carlos Paya Nominated to Board of Directors - - New Executives Appointed to Leadership Team.
Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care - Collegium Pharmaceutical ( NASDAQ:COLL )
STOUGHTON, Mass., March 10, 2025 ( GLOBE NEWSWIRE ) -- Collegium Pharmaceutical, Inc.
Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care
STOUGHTON, Mass., March 10, 2025 ( GLOBE NEWSWIRE ) -- Collegium Pharmaceutical, Inc. ( Nasdaq: COLL ) today announced it will have two poster presentations highlighting real-world data from its differentiated neuropsychiatry product, Jornay PM, ( methylphenidate HCl ) , a central nervous system ...
Collegium Pharmaceutical ( COLL ) Q4 Earnings and Revenues Beat Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 14.94% and 0.86%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Seeking Clues to Collegium Pharmaceutical ( COLL ) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Evaluate the expected performance of Collegium Pharmaceutical (COLL) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025
STOUGHTON, Mass., Feb. 13, 2025 ( GLOBE NEWSWIRE ) -- Collegium Pharmaceutical, Inc. ( Nasdaq: COLL ) today announced that it will report fourth quarter and full-year 2024 financial results after the market closes on Thursday, February 27, 2025.
Collegium's Revenue Outlook And CNS Expansion Signal Undervalued Opportunity, Says Needham - Collegium Pharmaceutical ( NASDAQ:COLL )
Collegium's 2025 guidance surpasses estimates with projected sales of $735-$750M and adjusted EBITDA of $435-$450M. Analyst highlights growth potential from Jornay PM and strong pain portfolio, while noting undervaluation due to opioid focus. Get 5 New Stock Recommendations Every Week
Collegium Provides 2025 Financial Guidance and Business Update
- Product Revenues, Net Expected in the Range of $735 Million to $750 Million ...
Is Collegium Pharmaceutical ( COLL ) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is the Options Market Predicting a Spike in Collegium Pharmaceutical ( COLL ) Stock?
Investors need to pay close attention to Collegium Pharmaceutical (COLL) stock based on the movements in the options market lately.
Collegium Pharmaceutical ( COLL ) Q3 Earnings and Revenues Lag Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -3.01% and 0.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Jazz Pharmaceuticals ( JAZZ ) Q3 Earnings and Revenues Top Estimates
Jazz (JAZZ) delivered earnings and revenue surprises of 20.84% and 1.75%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Corcept Therapeutics Stock Surges 61% in 2024: A Must Buy?
Investors should invest in CORT right now as the stock is doing extremely well in 2024 and its prospects look even brighter.
Collegium Pharmaceutical ( COLL ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will a Strong Evernorth Unit Benefit Cigna in Q3 Earnings?
CI's Q3 results are likely to be aided by strength in the specialty pharmacy business, partly offset by elevated medical costs resulting from higher utilization trends.
Will Higher Expense Level Be a Woe for Humana in Q3 Earnings?
HUM's Q3 results are likely to suffer from decline in commercial fully-insured premiums and higher operating costs, partly offset by a well-performing Medicare business.
Collegium Pharmaceutical to Report Q3 Earnings: What's in the Cards?
COLL's Q3 performance is likely to have benefited from higher revenues from the sales of its pain-management drugs and the newly acquired neurology drug.
Should Value Investors Buy Collegium Pharmaceutical ( COLL ) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Indivior PLC ( INDV ) Surpasses Q3 Earnings and Revenue Estimates
Indivior (INDV) delivered earnings and revenue surprises of 38.46% and 1.57%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Are Investors Undervaluing Collegium Pharmaceutical ( COLL ) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Collegium Pharmaceutical ( COLL ) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Collegium Pharmaceutical Insider Trades Send A Signal - Collegium Pharmaceutical ( NASDAQ:COLL )
On September 17, a recent SEC filing unveiled that Thomas B Smith, EVP and Chief Medical Officer at Collegium Pharmaceutical COLL made an insider sell. What Happened: Smith's recent Form 4 filing with the U.S. Securities and Exchange Commission on Tuesday unveiled the sale of 9,593 shares of ...
Are Medical Stocks Lagging Context Therapeutics Inc. ( CNTX ) This Year?
Here is how Context Therapeutics Inc. (CNTX) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.
Collegium Pharmaceutical ( COLL ) Upgraded to Buy: Here's Why
Collegium Pharmaceutical (COLL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Should Value Investors Buy Collegium Pharmaceutical ( COLL ) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Opioid Overdose Treatment Market is Projected to Reach US$ 3.1 Billion by 2034 | Fact.MR Report
Rockville, MD, Sept. 09, 2024 ( GLOBE NEWSWIRE ) -- The global opioid overdose treatment market is expected to reach a value of US$ 1.54 billion in 2024, as revealed in a new industry analysis published by proficient researchers at Fact.MR, a market research and competitive intelligence provider.
S&P Global To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Thursday - S&P Global ( NYSE:SPGI )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler cut the price target for C3.ai, Inc. AI from $29 to $24.
Collegium Completes Acquisition of Ironshore Therapeutics - Collegium Pharmaceutical ( NASDAQ:COLL )
- Adds Commercial Product Jornay PM®, Establishing Collegium's Presence in Neurology ( ADHD ) - - Collegium Updates 2024 Financial Guidance to Reflect Expected Immediate Accretion from the Ironshore Acquisition - - 2024 Product Revenues, Net Expected in the Range of $620.0 Million to $635.0 ...
Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference - Collegium Pharmaceutical ( NASDAQ:COLL )
STOUGHTON, Mass., Aug. 30, 2024 ( GLOBE NEWSWIRE ) -- Collegium Pharmaceutical, Inc. COLL, a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat ...
Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference
STOUGHTON, Mass., Aug. 30, 2024 ( GLOBE NEWSWIRE ) -- Collegium Pharmaceutical, Inc. ( Nasdaq: COLL ) , a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a ...
Collegium Pharmaceutical ( COLL ) Beats Q2 Earnings and Revenue Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 3.85% and 1.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Unveiling Collegium Pharmaceutical ( COLL ) Q2 Outlook: Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Collegium Pharmaceutical (COLL), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
